Research progress in anticoagulation intensity of warfarin in the elderly patients with non-valvular atrial fibrillation
Received:September 15, 2018  Revised:October 11, 2018
View Full Text  View/Add Comment  Download reader
DOI:
Key words:elderly;non-valvular atrial fibrillation;warfarin;
Author NameAffiliationE-mail
GU Min Department of Cardiovascular Diseases, School of Clinical Medicine, Yangzhou University 1624352911@qq.com 
GU Xiang Department of Cardiovascular Diseases, School of Clinical Medicine, Yangzhou University guxiang@yzu.edu.cn 
Hits: 90
Download times: 
Abstract:
      Epidemiological survey results show that the incidence of atrial fibrillation has increased year by year, especially in the elderly,when the age is older,the rate of morbidity and mortality is higher.The results of several clinical trials show that warfarin is still the main drug for the treatment of atrial fibrillation. In the guidelines of atrial fibrillation in Europe and the United States, it is recommended to control the international normalized ratio between 2.0 and 3.0, but there are racial differences between Asian and European and American populations. The anticoagulant intensity of warfarin should be appropriately lowed, especially for patients with high stroke and bleeding risks. In elderly patients with non-valvular atrial fibrillation, international normalized ratio controlled within the range of 1.5-2.5 is safe and effective, but this conclusion still lacks a large number of clinical trials and evidence-based medicine.
Close